Galectin Therapeutics Stock (NASDAQ: GALT) stock price, news, charts, stock research, profile.
Open | $3.230 |
Close | $3.500 |
Volume / Avg. | 212.084K / 148.392K |
Day Range | 3.200 - 3.550 |
52 Wk Range | 1.280 - 4.268 |
Market Cap | $220.253M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 60 |
Short Interest | 7.59% |
Days to Cover | 18.26 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Galectin Therapeutics (NASDAQ: GALT) through any online brokerage.
Other companies in Galectin Therapeutics’s space includes: Zura Bio (NASDAQ:ZURA), Outlook Therapeutics (NASDAQ:OTLK), Innate Pharma (NASDAQ:IPHA), Adverum Biotechnologies (NASDAQ:ADVM) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on Tuesday, April 9, 2024. The analyst firm set a price target for 11.00 expecting GALT to rise to within 12 months (a possible 209.16% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Galectin Therapeutics (NASDAQ: GALT) is $3.558 last updated April 25, 2024 at 5:01 PM EDT.
There are no upcoming dividends for Galectin Therapeutics.
Galectin Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Galectin Therapeutics.
Galectin Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.